JPS6367859B2 - - Google Patents

Info

Publication number
JPS6367859B2
JPS6367859B2 JP8734181A JP8734181A JPS6367859B2 JP S6367859 B2 JPS6367859 B2 JP S6367859B2 JP 8734181 A JP8734181 A JP 8734181A JP 8734181 A JP8734181 A JP 8734181A JP S6367859 B2 JPS6367859 B2 JP S6367859B2
Authority
JP
Japan
Prior art keywords
groups
group
phosphite
phenyl group
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP8734181A
Other languages
Japanese (ja)
Other versions
JPS57201852A (en
Inventor
Seiichiro Honda
Kazuhiko Kamyoshi
Hideo Anraku
Hiroyoshi Hata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sekisui Chemical Co Ltd
Original Assignee
Sekisui Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sekisui Chemical Co Ltd filed Critical Sekisui Chemical Co Ltd
Priority to JP8734181A priority Critical patent/JPS57201852A/en
Publication of JPS57201852A publication Critical patent/JPS57201852A/en
Publication of JPS6367859B2 publication Critical patent/JPS6367859B2/ja
Granted legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Description

【発明の詳现な説明】 本発明は血液怜査甚容噚に関し、詳しくは、被
怜者の党血詊料から遠心分離により、血枅を分離
するために甚いる有底の管状容噚、所謂スピツツ
に関する。 近幎、怜査技術の目ざたしい進歩ず盞俟぀お、
血枅生化孊怜査、血枅免疫孊怜査、血球怜査等の
血液怜査が広く普及し、病気予防や早期蚺断に倧
きく貢献するに至぀おいる。血枅怜査は、血液怜
査の䞻䜓をなしおおり、怜査に芁する血枅は通
垞、血液怜査甚容噚に採取した血液を凝固させた
埌、遠心分離によ぀お、比重の異なる血逅フむ
ブリンず血球が混合したゲル様塊状物から分離
しおいる。 埓来の血液怜査甚容噚ずしおは、ガラス補のも
の、及び、ポリスチレン、ポリメチルメタクリレ
ヌト、ポリ゚チレン等の合成暹脂補のものが䜿甚
されおいるが、これらは抂しお以䞋の欠点を持぀
おいる。 䞀぀は血液怜査甚容噚に血液を泚入した埌、凝
固に至るたでにかなりの時間を必芁ずし、迅速に
怜査を実斜するこずができない点であり、特に緊
急に怜査を実斜する必芁のある堎合に問題ずな぀
おいる。最も血液凝固時間が短かいずされるガラ
ス補血液怜査甚容噚でさえ、血液を泚入した埌凝
固に至るたでに40分ないし60分を必芁ずし、合成
暹脂補血液怜査甚容噚に至぀おは、血液凝固する
たでに、時間以䞊の攟眮を必芁ずする。 埓来の血液怜査甚容噚の有するいたひず぀の欠
点は、凝固した党血を遠心分離等の手段によ぀お
比重の異なる血枅ず血逅に盞分離させお、怜査に
䜿甚する玔粋な血枅を採取するに際し、血枅の分
離性が抂しお䞍良であるこずである。 即ちゲル状のフむブリンあるいは血逅が管壁に
匷固に付着し易く、そのため、血枅の採取量を極
端に枛少させる問題があり、又、血枅䞭にフむブ
リンが残存し易く、そのため、血枅生化孊怜査に
障害をひき起こすなどの問題が存しおいた。そし
お血枅分離性が比范的良奜ずされるガラス補血液
怜査甚容噚でさえ、15℃以䞋の䜎枩状態、特に冬
期䜿甚においお、䞊蚘の問題を頻発させおいる。 本発明者らは、䞊蚘の欠点を解消するため、血
液凝固を促進する䜜甚を有する物質構造を怜蚎し
特に、血液凝固因子を最も有効に掻性化するため
に、血液怜査甚容噚の内壁面圢成材料に存圚させ
るべき物質構造を鋭意研究した結果、血液凝固䜜
甚の顕著な物質ずしお、亜リン酞゚ステルを芋出
し、これが血液凝固に芁する時間を倧幅に短瞮さ
せるず共に血枅成分ず血逅成分を良奜に分離でき
るこずを芋出し、又曎に、これず2′
4′−テトラヒドロキシベンゟプノン、カテコヌ
ル誘導䜓、p′−む゜プロピリデンゞプノヌ
ルを䜵甚するこずにより盞乗的効果を埗られるこ
ずを芋出し本発明を完成するに至぀た。 本発明の芁旚ずするずころは、  内壁面圢成材料に、 匏 䞊匏においお、R1R2R3はいずれもプ
ニル基、又は該プニル基の氎玠原子の〜個
がノニル基もしくはオクチル基によ぀お眮換され
たアルキルプニル基であるか、R1R2R3の
うち䞀もしくは二がプニル基、又は該プニル
基の氎玠原子の〜個がノニル基もしくはオク
チル基によ぀お眮換されたアルキルプニル基で
あり、他がデシル基である。 で衚わされる亜リン酞゚ステルを存圚させおいる
こずを特城ずする、血液怜査甚容噚、  内壁面圢成材料に、 匏 䞊匏においお、R1R2R3はいずれもプ
ニル基、又は該プニル基の氎玠原子の〜個
がノニル基もしくはオクチル基によ぀お眮換され
たアルキルプニル基であるか、R1R2R3の
うち䞀もしくは二がプニル基、又は該プニル
基の氎玠原子の〜個がノニル基もしくはオク
チル基によ぀お眮換されたアルキルプニル基で
あり、他がデシル基である。 で衚わされる亜リン酞゚ステル重量郚ず、
2′4′−テトラヒドロキシベンゟプノン0.1
乃至3.0重量郚ずを存圚させおいるこずを特城ず
する、血液怜査甚容噚、  内壁面圢成材料に、 匏 䞊匏においお、R1R2R3はいずれもプ
ニル基、又は該プニル基の氎玠原子の〜個
がノニル基もしくはオクチル基によ぀お眮換され
たアルキルプニル基であるか、 R1R2R3のうち䞀もしくは二がプニル基、
又は該プニル基の氎玠原子の〜個がノニル
基もしくはオクチル基によ぀お眮換されたアルキ
ルプニル基であり、他がデシル基である。 で衚わされる亜リン酞゚ステル重量郚ず、−
タヌシダリブチルカテコヌル、−タヌシダリブ
チルカテコヌル、パラタヌシダリブチルカテコヌ
ル、カテキンおよびノルゞヒドロガダレチツク酞
から遞ばれるカテコヌル誘導䜓0.1乃至5.0重量郹
ずを存圚させおいるこずを特城ずする、血液怜査
甚容噚、  内壁面圢成材料に、 匏 䞊匏においお、R1R2R3はいずれもプ
ニル基、又は該プニル基の氎玠原子の〜個
がノニル基もしくはオクチル基によ぀お眮換され
たアルキルプニル基であるか、 R1R2R3のうち䞀もしくは二がプニル基、
又は該プニル基の氎玠原子の〜個がノニル
基もしくはオクチル基によ぀お眮換されたアルキ
ルプニル基であり、他がデシル基である。で
衚わされる亜リン酞゚ステル重量郚ずP′−
む゜プロピリデンゞプノヌル0.1乃至5.0重量郹
ずを存圚させおいるこずを特城ずする、血液怜査
甚容噚に存する。 次に本発明血液怜査甚容噚に぀いお曎に詳现に
説明する。 本発明においお、血液怜査甚容噚、即ちスピツ
ツの玠材ずしおは、熱可塑性暹脂、熱硬化性暹
脂、倉性倩然暹脂のいずれもが甚いられる。熱可
塑性暹脂ずしおは、䟋えばポリ゚チレン、ポリプ
ロピレン、ポリ−−メチルペンテン−、ポリ
スチレン、ポリメチルメタクリレヌト、ポリ塩化
ビニル、ポリ゚チレンテレフタレヌト、ポリブチ
レンテレフタレヌト、スチレン−アクリロニトリ
ル共重合䜓、スチレン−ブタゞ゚ン共重合䜓、ス
チレン−む゜プレン共重合䜓、スチレン−無氎マ
レむン酞共重合䜓、スチレン−アクリル酞共重合
䜓、スチレン−メチルメタクリレヌト共重合䜓、
゚チレン−プロピレン共重合䜓、スチレン−アク
リル酞共重合䜓、゚チレン−アクリル酞゚ステル
共重合䜓、ポリビニルアルコヌルアセタヌル化
物、ポリビニルアルコヌルブチラヌル化物等、た
た熱硬化性暹脂ずしおは、䟋えば、䞍飜和ポリ゚
ステル暹脂、゚ポキシ暹脂、゚ポキシ−アクリレ
ヌト暹脂等が甚いられる。 倉性倩然暹脂ずしおは、酢酞セルロヌス、プロ
ピオン酞セルロヌス、酢酞酪酞セルロヌス、゚チ
ルセルロヌス、゚チルキチン等が甚いられる。 本発明血液怜査甚容噚においおは、内壁面に血
液凝固促進䜜甚を有する亜リン酞゚ステルを存圚
させおいる。 かゝる亜リン酞゚ステルずしおは、 匏 䞊匏においお、R1R2R3はいずれもプ
ニル基、又は該プニル基の氎玠原子の〜個
がノニル基もしくはオクチル基によ぀お眮換され
たアルキルプニル基であるか、R1R2R3の
うち䞀もしくは二がプニル基、又は該プニル
基の氎玠原子の〜個がノニル基もしくはオク
チル基によ぀お眮換されたアルキルプニル基で
あり、他がデシル基である。 で衚わされるものが䜿甚される。 そしお䞊匏においお、本発明においお䜿甚に適
した亜リン酞゚ステルは、R1R2R3の皮類に
より次の通りに分類される。 (1) R1R2R3がいずれもプニル基又はアル
キルプニル基である堎合 䟋えばトリスプニルホスフアむト、トリス
モノノニルプニルホスフアむト、トリス
ゞノニルプニルホスフアむト、トリス
トリノニルプニルホスフアむト、トリス
モノオクチルプニルホスフアむト、トリ
スゞオクチルプニルホスフアむト、トリ
ストリオクチルプニルホスフアむト等が
存する。 (2) R1R2がプニル基又はアルキルプニル
基であ぀お、R3がアルキル基の堎合 䟋えばゞプニルデシルホスフアむト、ゞ
モノノニルプニルデシルホスフアむト、
ゞゞノニルプニルデシルホスフアむト、
ゞトリノニルプニルデシルホスフアむ
ト、ゞモノオクチルプニルデシルホスフ
アむト、ゞゞオクチルプニルデシルホス
フアむト、ゞトルオクチルプニルデシル
ホスフアむト等が存する。 (3) R1がプニル基又はアルキルプニル基で
あ぀お、R2R3がアルキル基の堎合 䟋えばプニルトリデシルホスフアむト、ノ
ニルプニルゞデシルホスフアむト、ゞノニル
プニルゞデシルホスフアむト、トリノニルフ
゚ニルゞデシルホスフアむト、モノオクチルフ
゚ニルゞデシルホスフアむト、ゞオクチルプ
ニルゞデシルホスフアむト、トリオクチルプ
ニルゞデシルホスフアむト等が存する。 そしお䞊蚘の血液凝固䜜甚を有する亜リン酞゚
ステルのうち、特に奜適に䜿甚されるものずしお
は、トリスモノノニルプニルホスフアむ
ト、トリスゞノニルプニルホスフアむト、
トリストリノニルプニルホスフアむト、ゞ
デシルプニルホスフアむト、ゞプニルデシル
ホスフアむト等である。 内壁面圢成材料に前蚘の亜リン酞゚ステルを存
圚させるずは、亜リン酞゚ステルを内壁衚面だけ
でなく壁内郚局にも存圚させる堎合のこずをい
う。 本発明血液怜査甚容噚は次の方法にお、補造す
るこずができる。成圢材料ずしおの暹脂に予め、
前蚘の亜リン酞゚ステルを䞀様に混合し、これを
射出成型、ブロヌ成型、圧瞮成圢、トランスフア
ヌ成圢、真空成圢、キダスト成圢等適宜の成圢方
法によ぀お成圢する。この方法によれば血液怜査
甚容噚の壁党䜓に、衚面だけでなく、厚さ方向に
も、前蚘の亜リン酞゚ステルが分散されおおり、
成圢埌、攟眮されおいる間に、分散されおいる前
蚘の亜リン酞゚ステルが次第に血液怜査甚容噚の
衚面ぞ移行するこずによ぀お、血液凝固促進に有
効な衚面が圢成される。前蚘の亜リン酞゚ステル
の血液怜査甚容噚の内壁面ぞの移行をより有効に
起させる手段ずしおブリヌドアりト促進物質を成
圢材料ずしおの暹脂䞭に、予め前蚘の亜リン酞゚
ステルず共に混合しおおくのが奜適である。 ブリヌドアりト促進物質ずしおは、高玚脂肪族
アルコヌル、高玚脂肪族カルボン酞、ハむドロカ
ヌボンワツクス、等の䜿甚が有効である。 前蚘の亜リン酞゚ステルは容噚の内壁衚面䞊に
僅かな量が存圚する堎合においおも血液凝固促進
䜜甚が認められるが、実甚䞊奜適には、衚面積圓
りの存圚量が、×10-6cm2以䞊であるこず
が望たしい。又、䜙り倚量に存圚する堎合には、
血枅怜査を劚害するこずがあるため、×10-3
cm2以䞋ずする事が望たしい。 䞊蚘の堎合においお前蚘の亜リン酞゚ステルを
単独で存圚させる堎合に、顕著な血液凝固促進効
果が認められる。 しかしながら前蚘の亜リン酞゚ステルず
2′4′−テトラヒドロキシベンゟプノン、
カテコヌル誘導䜓又はp′−む゜プロピリデン
ゞプノヌルを䜵甚するこずにより血液凝固促進
効果を䞀局すぐれたものずするこずができる。前
蚘の亜リン酞゚ステルず䜵甚されるこずにより盞
乗的に血液凝固促進効果を発揮する物質の䞀぀
は、2′4′−テトラヒドロキシベンゟフ
゚ノンである。 2′4′−テトラヒドロキシベンゟプ
ノンは次の化孊構造匏を有する。 2′4′−テトラヒドロキシベンゟプ
ノンは融点が195℃、溶媒に察する溶解性は30℃
で氎に察し0.1重量、メタノヌルに察し50重量
、゚タノヌルに察し40重量、氎−゚タノヌル
の溶液に察し10重量である。 又、最倧吞収波長䜍眮は345Όであり、カラ
ヌバリナヌガヌドナヌは重量のメタノヌ
ル溶液においおNo.である。 2′4′−テトラヒドロキシベンゟプ
ノンの䜿甚重量比率は亜リン酞゚ステルに察
し、0.1乃至3.0が奜適である。 前蚘亜リン酞゚ステルず䜵甚されるこずにより
盞乗的に血液凝固促進䜜甚を発揮する他の物質は
カテコヌル誘導䜓である。 カテコヌル誘導䜓ずしおは次の匏で衚わされる
ものが䜿甚される。 䞊匏の堎合においおカテコヌル誘導䜓は、R1
R2R3の皮類により−アルキルカテコヌル、
−アルキルカテコヌル、パラアルキルカテコヌ
ル、カテキン、ノルゞヒドロガダレチツク酞゚ラ
ゞン酞等に分けられる。そしおこれらの䞭でも特
に盞乗効果を顕著に瀺すものは、−タヌシダリ
ブチルカテコヌル、−タヌシダリブチルカテコ
ヌル、パラタヌシダリブチルカテコヌル、カテキ
ン、ノルゞヒドロガダレチツク酞である。 前蚘カテコヌル誘導䜓の䜿甚重量比重は前蚘亜
リン酞゚ステルに察し0.1乃至5.0が奜適であ
る。 前蚘亜リン酞゚ステルず䜵甚されるこずにより
盞乗的に血液凝固促進効果を発揮する他の物質は
p′−む゜プロピリデンゞプノヌルである。
これはビスプノヌルずしお商品化されおいる
物質であり、゚ポキシ暹脂の補造原料ずしお䜿甚
されおきたが、血液凝固促進効果を有するこずは
知られおいなか぀た。p′−む゜プロピリデン
ゞプノヌルの䜿甚重量比率は、前蚘亜リン酞゚
ステルに察し0.1乃至5.0が奜適である。 本発明血液怜査甚容噚によれば血液凝固因子が
迅速に掻性化せしめられ、血液凝固に芁する時間
が著しく短瞮されるず共に血枅ず血逅ずの分離が
容易に行なわれ、分離採取された血枅䞭に残存フ
むブリンや血逅成分が混入する問題も解消され、
曎には血逅成分の収瞮が十分に進行する結果、血
枅の収量が著しく倧きくなる効果が埗られる。 埓぀お、本発明血液怜査甚容噚は血液怜査甚採
血管、血液分離目的も有する採血甚シリンゞ、血
枅分離容噚等の甚途に奜適に䜿甚するこずができ
る。 実斜䟋  ポリプロピレン100重量郚圓りトリスモノノ
ニルプニルホスフアむト1.5重量郚を添加し
た成圢材料を射出成圢し、倖埄17、内埄15
、高さ110の血液怜査甚容噚を埗た。 この血液怜査甚容噚に人新鮮血c.c.を泚入した
埌20℃で攟眮しお、党血が完党に流動しなくなる
たでに芁した時間を血液凝固時間ずしお枬定し、
血液凝固性を評䟡した。 血液凝固埌、盎ちに3000回転毎分の回転速床
で、分間遠心分離を行ない、血枅分離状態を芳
察するず共に、䞊柄み血枅をピペツトにお採取
し、その量を血枅収量ずした。 衚の実斜䟋の欄の結果から明らかなよう
に、本発明の血液怜査甚容噚は、血液凝固が極め
お速やかであり、血枅分離状態も良奜であ぀た。 実斜䟋 〜 実斜䟋においおトリスモノノニルプニ
ルホスフアむト1.5重量郚の代りにトリスゞ
ノニルプニルホスフアむト2.0重量郚を䜿甚
した組成の成圢材料実斜䟋、トリスモノ
ノニルプニルホスフアむト1.5重量郚の代り
にゞプニルデシルホスフアむト2.0重量郚を䜿
甚した組成の成圢材料実斜䟋から倫々実斜
䟋ず同様にしお血液怜査甚容噚を埗た。 次いでこの血液怜査甚容噚を䜿甚し、実斜䟋
ず同様にしお血液凝固性、血枅分離状態、血枅収
量を評䟡した。その結果を衚の実斜䟋の
欄に瀺す。 実斜䟋 〜 スチレン−ブタゞ゚ン共重合䜓100重量郚圓り、
トリスゞノニルプニルホスフアむト1.5重
量郚、2′4′−テトラヒドロキゞベンゟ
プノン0.7重量郚を䜵甚した組成の成圢材料
実斜䟋、スチレン−ブタゞ゚ン共重合䜓100
重量郚圓り、トリスゞノニルプニルホスフ
アむト1.5重量郚、−タヌシダリヌブチルカテ
コヌル0.7重量郚を䜵甚した組成の成圢材料実
斜䟋、スチレン−ブタゞ゚ン共重合䜓100重量
郚圓り、トリスゞノニルプニルホスフアむ
ト1.5重量郚、p′−む゜プロピリデンゞプ
ノヌル0.7重量郚を䜵甚した組成の成圢材料実
斜䟋を甚いお倫々実斜䟋ず同様に血液怜査
甚容噚を埗た。 次いでこの血液怜査甚容噚を䜿甚し、実斜䟋
ず同様にしお血液凝固性、血枅分離状態、血枅収
量を評䟡した。その結果は衚の実斜䟋〜の
欄に瀺すが、血液凝固促進における顕著な盞乗効
果が認められるず共に血枅分離状態も極めお良奜
であ぀た。 比范䟋 〜 実斜䟋におけるず同䞀寞法の垂販のポリスチ
レン補血液怜査甚容噚比范䟋、ポリプロピ
レン補血液怜査甚容噚比范䟋及びポリメチ
ルメタクリレヌト補血液怜査甚容噚比范䟋
を甚意し、実斜䟋におけるず同条件䞋に血液凝
固性、血枅分離状態、血枅収量を評䟡したが、血
液凝固時間が著しく長時間ずなり、又血枅分離状
態も䞍良であ぀た。 【衚】
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a blood test container, and more particularly to a so-called spitz, a bottomed tubular container used for separating serum from a whole blood sample of a subject by centrifugation. In recent years, coupled with the remarkable progress in inspection technology,
Blood tests such as serum biochemical tests, serum immunological tests, and hematology tests have become widely used, and have come to greatly contribute to disease prevention and early diagnosis. Serum tests are the main body of blood tests, and the serum required for tests is usually obtained by coagulating blood collected in a blood test container and then centrifuging it to form blood clots with different specific gravities (fibrin and blood cells). separated from the mixed gel-like mass). Conventional blood test containers are made of glass and synthetic resins such as polystyrene, polymethyl methacrylate, and polyethylene, but these generally have the following drawbacks. One is that it takes a considerable amount of time for blood to coagulate after it is injected into a blood test container, making it impossible to carry out tests quickly, especially when tests need to be carried out urgently. has become a problem. Even glass blood test containers, which are said to have the shortest blood clotting time, require 40 to 60 minutes for blood to coagulate after being injected, and synthetic resin blood test containers... It takes 4 hours or more for the blood to coagulate. Another drawback of conventional blood test containers is that they require a method such as centrifugation to phase-separate coagulated whole blood into serum and blood clots with different specific gravities to collect pure serum for use in tests. , serum separability is generally poor. In other words, gel-like fibrin or blood clots tend to adhere firmly to the tube wall, which causes the problem of drastically reducing the amount of serum collected.Furthermore, fibrin tends to remain in the serum, which makes it difficult to perform serum biochemical tests. There were problems such as causing problems. Even glass blood test containers, which are said to have relatively good serum separation, frequently suffer from the above-mentioned problems when used at low temperatures of 15° C. or lower, especially during winter. In order to eliminate the above-mentioned drawbacks, the present inventors investigated the structure of substances that have the effect of promoting blood coagulation, and in particular, in order to most effectively activate blood coagulation factors, the inventors of the present invention have investigated the formation of the inner wall surface of blood test containers. As a result of intensive research into the substance structure that should be present in the material, we discovered phosphite as a substance with a remarkable blood coagulation effect, and found that this significantly shortened the time required for blood coagulation and improved the concentration of serum and clot components. We found that it was possible to separate this from 2, 2', 4,
The present inventors have discovered that a synergistic effect can be obtained by using 4'-tetrahydroxybenzophenone, a catechol derivative, and p,p'-isopropylidene diphenol in combination, and have completed the present invention. The gist of the present invention is as follows: 1. Inner wall surface forming material, formula: (In the above formula, R 1 , R 2 , and R 3 are all phenyl groups, or alkylphenyl groups in which 1 to 3 hydrogen atoms of the phenyl group are substituted with nonyl groups or octyl groups. , one or two of R 1 , R 2 , and R 3 is a phenyl group, or an alkyl phenyl group in which 1 to 3 hydrogen atoms of the phenyl group are substituted with a nonyl group or an octyl group, and others is a decyl group.) A container for blood testing, characterized in that a phosphite ester represented by the following formula is present: (In the above formula, R 1 , R 2 , and R 3 are all phenyl groups, or alkylphenyl groups in which 1 to 3 hydrogen atoms of the phenyl group are substituted with nonyl groups or octyl groups. , one or two of R 1 , R 2 , and R 3 is a phenyl group, or an alkyl phenyl group in which 1 to 3 hydrogen atoms of the phenyl group are substituted with a nonyl group or an octyl group, and others is a decyl group.) 1 part by weight of a phosphite ester represented by
2',4,4'-tetrahydroxybenzophenone 0.1
3. A container for blood testing, characterized in that the inner wall surface forming material is present with the formula: (In the above formula, R 1 , R 2 , and R 3 are all phenyl groups, or alkylphenyl groups in which 1 to 3 hydrogen atoms of the phenyl group are substituted with nonyl groups or octyl groups. , one or two of R 1 , R 2 , R 3 is a phenyl group,
Alternatively, the phenyl group is an alkylphenyl group in which 1 to 3 hydrogen atoms are substituted with a nonyl group or an octyl group, and the others are decyl groups. ) 1 part by weight of a phosphite ester represented by
A blood test characterized by the presence of 0.1 to 5.0 parts by weight of a catechol derivative selected from tertiary butylcatechol, 4-tertiarybutylcatechol, paratertiarybutylcatechol, catechin, and nordihydrogayaretic acid. 4. For the inner wall surface forming material, the formula (In the above formula, R 1 , R 2 , and R 3 are all phenyl groups, or alkylphenyl groups in which 1 to 3 hydrogen atoms of the phenyl group are substituted with nonyl groups or octyl groups. , one or two of R 1 , R 2 , R 3 is a phenyl group,
Alternatively, the phenyl group is an alkylphenyl group in which 1 to 3 hydrogen atoms are substituted with a nonyl group or an octyl group, and the others are decyl groups. ) and 1 part by weight of phosphite ester represented by P, P'-
The present invention provides a blood test container characterized by containing 0.1 to 5.0 parts by weight of isopropylidene diphenol. Next, the blood test container of the present invention will be explained in more detail. In the present invention, any of thermoplastic resins, thermosetting resins, and modified natural resins can be used as the material for the blood test container, that is, the spittoon. Examples of thermoplastic resins include polyethylene, polypropylene, poly-4-methylpentene-1, polystyrene, polymethyl methacrylate, polyvinyl chloride, polyethylene terephthalate, polybutylene terephthalate, styrene-acrylonitrile copolymer, and styrene-butadiene copolymer. , styrene-isoprene copolymer, styrene-maleic anhydride copolymer, styrene-acrylic acid copolymer, styrene-methyl methacrylate copolymer,
Ethylene-propylene copolymer, styrene-acrylic acid copolymer, ethylene-acrylic acid ester copolymer, polyvinyl alcohol acetal, polyvinyl alcohol butyral, etc., and thermosetting resins include, for example, unsaturated polyester resin, Epoxy resin, epoxy-acrylate resin, etc. are used. As the modified natural resin, cellulose acetate, cellulose propionate, cellulose acetate butyrate, ethyl cellulose, ethyl chitin, etc. are used. In the blood test container of the present invention, a phosphite having a blood coagulation promoting effect is present on the inner wall surface. As such a phosphite ester, the formula (In the above formula, R 1 , R 2 , and R 3 are all phenyl groups, or alkylphenyl groups in which 1 to 3 hydrogen atoms of the phenyl group are substituted with nonyl groups or octyl groups. , one or two of R 1 , R 2 , and R 3 is a phenyl group, or an alkyl phenyl group in which 1 to 3 hydrogen atoms of the phenyl group are substituted with a nonyl group or an octyl group, and others is a decyl group.) is used. In the above formula, phosphorous esters suitable for use in the present invention are classified as follows depending on the types of R 1 , R 2 , and R 3 . (1) When R 1 , R 2 , and R 3 are all phenyl or alkylphenyl groups: For example, trisphenyl phosphite, tris (monononylphenyl) phosphite, tris (dinonylphenyl) phosphite, tris (torino) These include nilphenyl) phosphite, tris(monoctylphenyl) phosphite, tris(dioctyl phenyl) phosphite, tris(trioctylphenyl) phosphite, and the like. (2) When R 1 and R 2 are phenyl or alkylphenyl groups, and R 3 is an alkyl group: For example, diphenyldecyl phosphite, di(monononylphenyl)decyl phosphite,
di(dinonylphenyl)decyl phosphite,
Examples include di(trinonylphenyl)decyl phosphite, di(monooctyl phenyl) decyl phosphite, di(dioctyl phenyl) decyl phosphite, and di(toluoctylphenyl) decyl phosphite. (3) When R 1 is a phenyl group or an alkylphenyl group and R 2 and R 3 are alkyl groups: For example, phenyltridecyl phosphite, nonylphenyl didecyl phosphite, dinonylphenyl didecyl Examples include phosphite, trinonylphenyl didecyl phosphite, monooctylphenyl didecyl phosphite, dioctyl phenyl didecyl phosphite, trioctyl phenyl didecyl phosphite, and the like. Among the above-mentioned phosphorous esters having a blood coagulation effect, those which are particularly preferably used include tris(mononylphenyl) phosphite, tris(dinonylphenyl) phosphite,
These include tris(trinonylphenyl) phosphite, didecyl phenyl phosphite, diphenyl decyl phosphite, and the like. Presence of the above-mentioned phosphite in the inner wall forming material refers to the case where the phosphite is present not only on the inner wall surface but also in the inner layer of the wall. The blood test container of the present invention can be manufactured by the following method. In advance, resin is used as a molding material.
The above-mentioned phosphite esters are uniformly mixed and molded by an appropriate molding method such as injection molding, blow molding, compression molding, transfer molding, vacuum molding, cast molding, or the like. According to this method, the phosphorous ester is dispersed throughout the wall of the blood test container, not only on the surface but also in the thickness direction.
After molding, while the container is left standing, the dispersed phosphite gradually migrates to the surface of the blood test container, thereby forming a surface effective for promoting blood coagulation. As a means to more effectively cause the transfer of the phosphite ester to the inner wall surface of the blood test container, a bleed-out promoting substance is mixed in advance with the phosphite ester into the resin serving as the molding material. is preferable. As the bleed-out accelerator, higher aliphatic alcohols, higher aliphatic carboxylic acids, hydrocarbon waxes, and the like are effective. Although the above-mentioned phosphite has a blood coagulation promoting effect even when present in a small amount on the inner wall surface of the container, it is preferable for practical use that the amount present per surface area is 1×10 -6 gr. / cm2 or more is desirable. Also, if there is too much,
1×10 -3 g as it may interfere with serum tests.
It is desirable that it be less than r/cm 2 . In the above case, when the phosphite ester is present alone, a significant blood coagulation promoting effect is observed. However, the above phosphite ester and 2,
2',4,4'-tetrahydroxybenzophenone,
By using a catechol derivative or p,p'-isopropylidene diphenol in combination, the effect of promoting blood coagulation can be further improved. One of the substances that exhibits a synergistic blood coagulation promoting effect when used in combination with the above-mentioned phosphite is 2,2',4,4'-tetrahydroxybenzophenone. 2,2',4,4'-tetrahydroxybenzophenone has the following chemical structure. 2,2',4,4'-tetrahydroxybenzophenone has a melting point of 195℃ and a solubility in solvents of 30℃.
0.1% by weight for water, 50% by weight for methanol, 40% by weight for ethanol, and 10% by weight for a 1:1 water-ethanol solution. Further, the maximum absorption wavelength position is 345 mΌ, and the color value (Gardner) is No. 8 in a 1% by weight methanol solution. The weight ratio of 2,2',4,4'-tetrahydroxybenzophenone to 1 part of phosphite is preferably 0.1 to 3.0. Other substances that synergistically exhibit a blood coagulation promoting effect when used in combination with the phosphite are catechol derivatives. As the catechol derivative, one represented by the following formula is used. In the case of the above formula, the catechol derivative is R 1 ,
Depending on the type of R 2 and R 3, 3-alkylcatechol,
It is divided into 4-alkylcatechol, para-alkylcatechol, catechin, nordihydrogayaretic acid, ellagic acid, etc. Among these, those which show particularly remarkable synergistic effects are 3-tert-butylcatechol, 4-tert-butylcatechol, para-tert-butylcatechol, catechin, and nordihydrogayaretic acid. The weight specific gravity of the catechol derivative used is preferably 0.1 to 5.0 based on 1 part of the phosphorous acid ester. Another substance that synergistically exhibits a blood coagulation promoting effect when used in combination with the phosphite is p,p'-isopropylidene diphenol.
This is a substance commercialized as bisphenol A, and has been used as a raw material for producing epoxy resins, but it was not known to have a blood coagulation promoting effect. The weight ratio of p,p'-isopropylidene diphenol to 1 part of the phosphite is preferably 0.1 to 5.0. According to the blood test container of the present invention, blood coagulation factors are activated rapidly, the time required for blood coagulation is significantly shortened, and serum and blood clots can be easily separated, and blood coagulation factors can be rapidly activated. The problem of contamination with residual fibrin and blood clot components has also been resolved.
Furthermore, as a result of sufficient contraction of the blood clot components, the yield of serum can be significantly increased. Therefore, the blood test container of the present invention can be suitably used for blood test blood collection tubes, blood collection syringes that also serve the purpose of blood separation, serum separation containers, and the like. Example 1 A molding material containing 1.5 parts by weight of tris(monononylphenyl) phosphite per 100 parts by weight of polypropylene was injection molded, and the outer diameter was 17 m/m and the inner diameter was 15 m.
A blood test container with a height of 110 m/m and a height of 110 m/m was obtained. After injecting 5 c.c. of fresh human blood into this blood test container, it was left at 20°C, and the time required for the whole blood to stop flowing completely was measured as the blood coagulation time.
Blood coagulability was evaluated. Immediately after blood coagulation, centrifugation was performed at a rotational speed of 3000 rpm for 5 minutes, and the state of serum separation was observed, and the supernatant serum was collected with a pipette, and the amount was taken as the serum yield. As is clear from the results in the Example 1 column of Table 1, the blood test container of the present invention coagulated blood extremely quickly and had good serum separation. Examples 2 to 3 A molding material having a composition in which 2.0 parts by weight of tris(dinonylphenyl) phosphite was used instead of 1.5 parts by weight of tris(monononylphenyl) phosphite in Example 1 (Example 2), tris(monononylphenyl) ) Blood test containers were obtained in the same manner as in Example 1 from the molding material (Example 3) using 2.0 parts by weight of diphenyldecyl phosphite instead of 1.5 parts by weight of phosphite. Next, using this blood test container, Example 1
Blood coagulability, serum separation status, and serum yield were evaluated in the same manner as above. The results are shown in the columns of Examples 2 and 3 in Table 1. Examples 4 to 6 Per 100 parts by weight of styrene-butadiene copolymer,
Molding material containing 1.5 parts by weight of tris(dinonylphenyl) phosphite and 0.7 parts by weight of 2,2',4,4'-tetrahydrokidibenzophenone (Example 4), styrene-butadiene copolymer 100
Molding material containing 1.5 parts by weight of tris(dinonylphenyl) phosphite and 0.7 parts by weight of 4-tert-butylcatechol (Example 5), per 100 parts by weight of styrene-butadiene copolymer, tris(dinonylphenyl) Blood test containers were obtained in the same manner as in Example 1 using a molding material (Example 6) having a composition containing 1.5 parts by weight of phosphite and 0.7 parts by weight of p,p'-isopropylidene diphenol. Next, using this blood test container, Example 1
Blood coagulability, serum separation status, and serum yield were evaluated in the same manner as above. The results are shown in the columns of Examples 4 to 6 in Table 1, and a remarkable synergistic effect in promoting blood coagulation was observed, as well as an extremely good serum separation condition. Comparative Examples 1 to 3 Commercially available polystyrene blood test containers with the same dimensions as in Example 1 (Comparative Example 1), polypropylene blood test containers (Comparative Example 2), and polymethyl methacrylate blood test containers (Comparative Example 3)
was prepared and evaluated for blood coagulation, serum separation state, and serum yield under the same conditions as in Example 1, but the blood coagulation time was extremely long and the serum separation state was also poor. 【table】

Claims (1)

【特蚱請求の範囲】  内壁面圢成材料に、 匏 䞊匏においお、R1R2R3はいずれもプ
ニル基、又は該プニル基の氎玠原子の〜個
がノニル基もしくはオクチル基によ぀お眮換され
たアルキルプニル基であるか、 R1R2R3のうち䞀もしくは二がプニル基、
又は該プニル基の氎玠原子の〜個がノニル
基もしくはオクチル基によ぀お眮換されたアルキ
ルプニル基であり、他がデシル基である。 で衚わされる亜リン酞゚ステルを存圚させおいる
こずを特城ずする、血液怜査甚容噚。  内壁面圢成材料に、 匏 䞊匏においお、R1R2R3はいずれもプ
ニル基、又は該プニル基の氎玠原子の〜個
がノニル基もしくはオクチル基によ぀お眮換され
たアルキルプニル基であるか、 R1R2R3のうち䞀もしくは二がプニル基、
又は該プニル基の氎玠原子の〜個がノニル
基もしくはオクチル基によ぀お眮換されたアルキ
ルプニル基であり、他がデシル基である。 で衚わされる亜リン酞゚ステル重量郚ず、
2′4′−テトラヒドロキシベンゟプノン
0.1乃至3.0重量郚ずを存圚させおいるこずを特
城ずする、血液怜査甚容噚。  内壁面圢成材料に 匏 䞊匏においお、R1R2R3はいずれもプ
ニル基、又は該プニル基の氎玠原子の〜個
がノニル基もしくはオクチル基によ぀お眮換され
たアルキルプニル基であるか、 R1R2R3のうち䞀もしくは二がプニル基、
又は該プニル基の氎玠原子の〜個がノニル
基もしくはオクチル基によ぀お眮換されたアルキ
ルプニル基であり、他がデシル基である。 で衚わされる亜リン酞゚ステル重量郚ず、−
タヌシダリブチルカテコヌル、−タヌシダリブ
チルカテコヌル、パラタヌシダリブチルカテコヌ
ル、カテキンおよびノルゞヒドロガダレチツク酞
から遞ばれるカテコヌル誘導䜓0.1乃至5.0重量郹
ずを存圚させおいるこずを特城ずする、血液怜査
甚容噚。  内壁面圢成材料に、 匏 䞊匏においお、R1R2R3はいずれもプ
ニル基、又は該プニル基の氎玠原子の〜個
がノニル基もしくはオクチル基によ぀お眮換され
たアルキルプニル基であるか、R1R2R3の
うち䞀もしくは二がプニル基、又は該プニル
基の氎玠原子の〜個がノニル基もしくはオク
チル基によ぀お眮換されたアルキルプニル基で
あり、他がデシル基である。 で衚わされる亜リン酞゚ステル重量郚ず
p′−む゜プロピリデンゞプノヌル0.1乃至5.0重
量郚ずを存圚させおいるこずを特城ずする、血液
怜査甚容噚。
[Claims] 1. The inner wall surface forming material has the following formula: (In the above formula, R 1 , R 2 , and R 3 are all phenyl groups, or alkylphenyl groups in which 1 to 3 hydrogen atoms of the phenyl group are substituted with nonyl groups or octyl groups. , one or two of R 1 , R 2 , R 3 is a phenyl group,
Alternatively, the phenyl group is an alkylphenyl group in which 1 to 3 hydrogen atoms are substituted with a nonyl group or an octyl group, and the others are decyl groups. ) A blood test container characterized by containing a phosphite ester represented by: 2 For the inner wall surface forming material, the formula (In the above formula, R 1 , R 2 , and R 3 are all phenyl groups, or alkylphenyl groups in which 1 to 3 hydrogen atoms of the phenyl group are substituted with nonyl groups or octyl groups. , one or two of R 1 , R 2 , R 3 is a phenyl group,
Alternatively, the phenyl group is an alkylphenyl group in which 1 to 3 hydrogen atoms are substituted with a nonyl group or an octyl group, and the others are decyl groups. ) 1 part by weight of a phosphite ester represented by
A container for blood testing, characterized in that 2',4,4'-tetrahydroxybenzophenone (0.1 to 3.0 parts by weight) is present. 3 Inner wall surface forming material: Formula (In the above formula, R 1 , R 2 , and R 3 are all phenyl groups, or alkylphenyl groups in which 1 to 3 hydrogen atoms of the phenyl group are substituted with nonyl groups or octyl groups. , one or two of R 1 , R 2 , R 3 is a phenyl group,
Alternatively, the phenyl group is an alkylphenyl group in which 1 to 3 hydrogen atoms are substituted with a nonyl group or an octyl group, and the others are decyl groups. ) 1 part by weight of a phosphite ester represented by
A blood test characterized by the presence of 0.1 to 5.0 parts by weight of a catechol derivative selected from tertiary butylcatechol, 4-tertiarybutylcatechol, paratertiarybutylcatechol, catechin, and nordihydrogayaretic acid. container. 4 For the inner wall surface forming material, the formula (In the above formula, R 1 , R 2 , and R 3 are all phenyl groups, or alkylphenyl groups in which 1 to 3 hydrogen atoms of the phenyl group are substituted with nonyl groups or octyl groups. , one or two of R 1 , R 2 , and R 3 is a phenyl group, or an alkyl phenyl group in which 1 to 3 hydrogen atoms of the phenyl group are substituted with a nonyl group or an octyl group, and others is a decyl group) and 1 part by weight of a phosphite represented by p,
A container for blood testing, characterized in that 0.1 to 5.0 parts by weight of p'-isopropylidene diphenol is present.
JP8734181A 1981-06-05 1981-06-05 Container for blood inspection Granted JPS57201852A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP8734181A JPS57201852A (en) 1981-06-05 1981-06-05 Container for blood inspection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8734181A JPS57201852A (en) 1981-06-05 1981-06-05 Container for blood inspection

Publications (2)

Publication Number Publication Date
JPS57201852A JPS57201852A (en) 1982-12-10
JPS6367859B2 true JPS6367859B2 (en) 1988-12-27

Family

ID=13912162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8734181A Granted JPS57201852A (en) 1981-06-05 1981-06-05 Container for blood inspection

Country Status (1)

Country Link
JP (1) JPS57201852A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06242106A (en) * 1993-02-01 1994-09-02 Becton Dickinson & Co Blood-gathering apparatus

Also Published As

Publication number Publication date
JPS57201852A (en) 1982-12-10

Similar Documents

Publication Publication Date Title
Claude Fractionation of mammalian liver cells by differential centrifugation: II. Experimental procedures and results
Perper et al. Purification of lymphocytes and platelets by gradient centrifugation
US10064404B2 (en) Stabilization of thrombocytes at ambient temperatures
EP2334307B1 (en) Multilayered blood product
FR2704418A1 (en) Tube containing an activator of blood coagulation and its method of preparation
Papahadjopoulos et al. Purification and properties of bovine factor V: A change of molecular size during blood coagulation
JP2550232B2 (en) Blood separating agent
JPS6367856B2 (en)
DE69221849T2 (en) Serum and plasma separating mixtures and blood test containers
JPS6367857B2 (en)
JPS6367859B2 (en)
JPH052015A (en) Blood separating agent
US4529711A (en) Fluid blood coagulation promoter
JPS6367660B2 (en)
JP2965359B2 (en) Blood test container
JPS606866A (en) Vessel for inspecting blood
US4088753A (en) Method of obtaining a splenic composition which inhibits platelet function and said composition
JPS6367858B2 (en)
JPS6319824B2 (en)
JPH0295257A (en) Composition for separation of blood component and vessel for blood inspection
JPS6367658B2 (en)
Grauer et al. Immunosuppressive serum factors in viral hepatitis. III. Prognostic relevance of rosette inhibitory factor and serum inhibition factor in acute and chronic hepatitis
JPH0126504B2 (en)
JPS596655B2 (en) Blood collection tube for serum separation
JPH0126025B2 (en)